Published in Cancer Res on February 01, 1998
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1999) 4.19
Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci U S A (2006) 2.97
Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell (2011) 2.40
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov (2011) 2.14
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal (2010) 1.94
The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest (2012) 1.86
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res (2010) 1.65
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer (2010) 1.21
Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer (2002) 1.16
Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg (2010) 1.10
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol (2001) 1.04
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch (2003) 1.03
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus. Br J Cancer (2001) 1.01
TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol (2009) 0.99
Comparative analysis of algorithms for integration of copy number and expression data. Nat Methods (2012) 0.97
Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One (2014) 0.97
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics (2011) 0.95
Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94
PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS One (2012) 0.94
Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol (2014) 0.91
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas. Mol Pathol (1999) 0.90
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen (2013) 0.89
The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Ther (2014) 0.86
Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol (2011) 0.86
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma. Head Neck (2014) 0.85
PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol (2008) 0.83
Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer (2001) 0.82
Oral cavity and oropharyngeal squamous cell carcinoma genomics. Otolaryngol Clin North Am (2013) 0.82
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer Metastasis Rev (2013) 0.82
Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol (2012) 0.81
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets (2015) 0.81
Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst (2015) 0.80
Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes Cancer (2016) 0.79
Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC). Oncotarget (2016) 0.77
Molecular Aspects of Head and Neck Cancer Therapy. Hematol Oncol Clin North Am (2015) 0.77
Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma. Oncotarget (2016) 0.76
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget (2017) 0.75
Genomic sequencing and precision medicine in head and neck cancers. Eur J Surg Oncol (2016) 0.75
Genes and proteins differentially expressed during in vitro malignant transformation of bovine pancreatic duct cells. Neoplasia (2007) 0.75
Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy. Sci Rep (2017) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
The human transcriptome map: clustering of highly expressed genes in chromosomal domains. Science (2001) 12.35
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A (1997) 8.27
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Head and neck cancer. N Engl J Med (2001) 7.32
The molecular basis of Turcot's syndrome. N Engl J Med (1995) 6.65
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Allelotype of colorectal carcinomas. Science (1989) 5.54
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med (1992) 4.58
The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature (1999) 4.55
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol (1994) 4.43
CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol (2000) 4.41
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Molecular diagnosis of familial adenomatous polyposis. N Engl J Med (1993) 4.07
Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet (1995) 4.01
Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity (1996) 3.91
A TATA box implicated in E1A transcriptional activation of a simple adenovirus 2 promoter. Nature (1987) 3.81
Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature (2000) 3.78
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
Evaluation of PCR-generated chimeras, mutations, and heteroduplexes with 16S rRNA gene-based cloning. Appl Environ Microbiol (2001) 3.76
Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr (1997) 3.75
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med (2001) 3.71
Scrambled exons. Cell (1991) 3.65
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature (1993) 3.48
The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med (2001) 3.39
Functions of the MDM2 oncoprotein. Cell Mol Life Sci (1999) 3.35
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med (1996) 3.33
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med (1995) 3.07
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95
Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol (2007) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest (2001) 2.87
The association between the quality of inpatient care and early readmission. Ann Intern Med (1995) 2.86
Molecular cloning and expression of the mouse ornithine decarboxylase gene. Proc Natl Acad Sci U S A (1984) 2.83
Early T lymphocyte progenitors. Annu Rev Immunol (1996) 2.81